Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1

Interventions

Gemcitabine 47Cisplatin 32pembrolizumab 28Paclitaxel 13Docetaxel 13avelumab 12Mitomycin 12atezolizumab 11Nivolumab 11Cystectomy 10Carboplatin 9durvalumab 7Sunitinib 7apaziquone 6Doxorubicin 6BCG Vaccine 65-aminolevulinic acid hexyl ester 6Vinblastine 5Radiation 5Platinum 5Methotrexate 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5Taxes 4Standard of Care 4Sorafenib 4Radiotherapy 4Fluorouracil 4Erlotinib Hydrochloride 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neoplasms × Pharmaceutical Preparations × Clear all
NCT00526656 2019-04-16

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
9 enrolled 5 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡